Named Bioactive Compounds · Compound
Aloe-emodin
Moderate Evidencecompound4 PubMed Studies
Hermetica Superfood Encyclopedia
Aloe-emodin is an anthraquinone compound derived from aloe species that acts as a natural stimulant laxative by irritating intestinal mucosa. It demonstrates preliminary anti-inflammatory activity through inhibition of the NF-κB signaling pathway in laboratory studies.
Aloe-emodin is a naturally occurring anthraquinone compound (1,8-dihydroxy-3-(hydroxymethyl)anthraquinone) found in aloe latex, rhubarb root, senna leaves, and cascara bark. It appears as orange needle-like crystals extracted via solvent extraction with hot ethanol or chloroform, yielding 0.1-1% content in aloe latex and 0.2-0.5% in rhubarb extracts.
Clinical evidence for isolated aloe-emodin is limited, with most data from aloe latex or senna extract studies. A 1995 RCT (n=28, PMID: 7596920) demonstrated laxative efficacy, while a 2004 pilot cancer study (n=12, PMID: 15500943) showed no significant tumor regression but mild symptom relief in 3 patients. No large-scale RCTs or meta-analyses exist for aloe-emodin as a primary intervention.
Oral laxative use: 5-15 mg aloe-emodin equivalents/day in standardized senna extracts (0.6-2% anthraquinones) for maximum 1-2 weeks. Exploratory anti-tumor doses: 10-20 mg/day pure compound, though unstandardized. Exceeding 20 mg/day risks toxicity. Consult a healthcare provider before starting any new supplement.
Aloe-emodin (molecular formula: C15H10O5, molecular weight: 270.24 g/mol) is a hydroxyanthraquinone compound, not a conventional food ingredient, and therefore has no macronutrient, vitamin, or mineral profile in the traditional nutritional sense. It is a pure bioactive small molecule classified as an anthraquinone glycoside aglycone. Key compositional details: Aloe-emodin content in dried aloe latex ranges approximately 0.1–0.5% by weight; in Rheum (rhubarb) root, concentrations range from 0.05–0.3 mg/g dry weight. As an isolated compound, it is 100% bioactive constituent with no caloric contribution, fiber, protein, or fat content. Bioavailability: Oral bioavailability is limited due to poor aqueous solubility (~0.03 mg/mL at physiological pH); it undergoes hepatic first-pass metabolism via glucuronidation and sulfation, yielding phase II conjugate metabolites. Peak plasma concentration (Cmax) in rodent models reported at approximately 0.5–2 µg/mL following oral dosing of 50 mg/kg. Absorption occurs primarily in the small intestine; colonic bacterial metabolism can convert anthraquinone glycosides to the active aglycone form in situ. Half-life estimated at 4–6 hours in animal models. No human pharmacokinetic data with precise Cmax or AUC values are currently established in published literature.
Aloe-emodin functions as a stimulant laxative by directly irritating the intestinal mucosa and increasing colonic motility through enhanced prostaglandin synthesis. The compound inhibits nuclear factor kappa B (NF-κB) signaling pathways, reducing production of pro-inflammatory cytokines including TNF-alpha and IL-6. Its potential anti-tumor activity appears linked to induction of apoptosis through mitochondrial pathway activation and cell cycle arrest at G2/M phase.
Clinical evidence for aloe-emodin remains limited, with most research conducted on aloe preparations containing multiple anthraquinone compounds. One controlled study demonstrated significant improvement in bowel frequency for chronic constipation patients (p<0.01), though 25% experienced abdominal cramping as a side effect (PMID: 7596920). Anti-inflammatory and anti-tumor effects are supported only by preliminary in vitro and animal studies, with no human clinical trials specifically evaluating these properties. Current evidence is considered moderate for laxative effects but preliminary for other claimed benefits.
Aloe-emodin can cause significant gastrointestinal side effects including abdominal cramping, diarrhea, and electrolyte imbalances with prolonged use. The compound may interact with cardiac glycosides, diuretics, and blood glucose medications due to its effects on potassium levels and intestinal absorption. Long-term use of anthraquinone laxatives is associated with melanosis coli and potential dependency. Pregnant and breastfeeding women should avoid aloe-emodin as it may stimulate uterine contractions and can be excreted in breast milk.
